(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.23%) $79.13
(0.10%) $2.04
(0.19%) $2 314.10
(0.36%) $26.93
(0.07%) $963.30
(-0.14%) $0.932
(-0.42%) $10.98
(-0.12%) $0.797
(-2.30%) $91.12
Live Chart Being Loaded With Signals
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders...
Stats | |
---|---|
Šios dienos apimtis | 1.06M |
Vidutinė apimtis | 214 738 |
Rinkos kapitalizacija | 123.37M |
EPS | $0 ( 2024-03-12 ) |
Kita pelno data | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.933 |
ATR14 | $0.143 (2.91%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-25 | Trask Anna | Sell | 106 864 | Common Stock |
2023-09-25 | Trask Anna | Sell | 45 000 | Stock Option (right to buy) |
2023-09-25 | Trask Anna | Sell | 52 500 | Stock Option (right to buy) |
2023-09-25 | Trask Anna | Sell | 137 302 | Stock Option (right to buy) |
2023-09-25 | Carson William H. | Sell | 5 000 | Common Stock |
INSIDER POWER |
---|
-72.58 |
Last 92 transactions |
Buy: 13 490 376 | Sell: 25 219 441 |
Tūris Koreliacija
Decibel Therapeutics, Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
BYFC | 0.916 |
BOOM | 0.915 |
MDXG | 0.906 |
ASLE | 0.893 |
CIGI | 0.893 |
SLMBP | 0.89 |
MBIN | 0.888 |
SNPO | 0.887 |
NEXT | 0.885 |
AIRS | 0.883 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
AMRB | -0.925 |
NETE | -0.87 |
MMAC | -0.862 |
LWAC | -0.846 |
CINC | -0.838 |
DWSH | -0.838 |
SRAC | -0.819 |
UMPQ | -0.806 |
NVEI | -0.801 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Decibel Therapeutics, Koreliacija - Valiuta/Žaliavos
Decibel Therapeutics, Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-2.52 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-2.52 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.08 |
FY | 2020 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.701 |
Financial Reports:
No articles found.
Decibel Therapeutics,
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.